Marco Chivalan

590 total citations
6 papers, 15 citations indexed

About

Marco Chivalan is a scholar working on Oncology, Radiology, Nuclear Medicine and Imaging and Pulmonary and Respiratory Medicine. According to data from OpenAlex, Marco Chivalan has authored 6 papers receiving a total of 15 indexed citations (citations by other indexed papers that have themselves been cited), including 6 papers in Oncology, 3 papers in Radiology, Nuclear Medicine and Imaging and 2 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Marco Chivalan's work include Cancer Treatment and Pharmacology (4 papers), HER2/EGFR in Cancer Research (2 papers) and Radiopharmaceutical Chemistry and Applications (2 papers). Marco Chivalan is often cited by papers focused on Cancer Treatment and Pharmacology (4 papers), HER2/EGFR in Cancer Research (2 papers) and Radiopharmaceutical Chemistry and Applications (2 papers). Marco Chivalan collaborates with scholars based in Guatemala, United States and Argentina. Marco Chivalan's co-authors include E Douglas Kramer, Francisco Barrios, Luis Fein, David L. Cutler, Hui Wang, Suyapa Bejarano, Hui Wang, Rubén Dario Kowalyszyn, Victor Puac‐Polanco and Hope S. Rugo and has published in prestigious journals such as Journal of Clinical Oncology, Cancer Research and International Journal of Radiation Oncology*Biology*Physics.

In The Last Decade

Marco Chivalan

6 papers receiving 15 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Marco Chivalan Guatemala 2 13 4 3 3 2 6 15
Toby Talbot United Kingdom 3 18 1.4× 5 1.3× 3 1.0× 2 0.7× 7 21
Dorothea Hanf Germany 3 8 0.6× 6 1.5× 4 1.3× 2 0.7× 3 19
John E. Doster United States 2 10 0.8× 2 0.5× 3 1.0× 3 1.0× 2 17
Graziella Bosco Spain 2 6 0.5× 3 0.8× 4 1.3× 3 1.0× 2 12
Laura Mattheis Germany 3 6 0.5× 4 1.0× 3 1.0× 5 1.7× 3 19
Dor Simkin Israel 2 7 0.5× 6 1.5× 2 0.7× 2 0.7× 3 12
Chi-Wan Chow United States 3 9 0.7× 2 0.5× 4 1.3× 3 1.0× 9 11
Filipa Cardoso Portugal 3 7 0.5× 3 0.8× 2 0.7× 2 0.7× 7 14
Rebecca Velickovic Australia 2 7 0.5× 6 1.5× 2 0.7× 2 0.7× 3 9
Esma’il Akade Iran 3 6 0.5× 3 0.8× 4 1.3× 3 1.0× 13 18

Countries citing papers authored by Marco Chivalan

Since Specialization
Citations

This map shows the geographic impact of Marco Chivalan's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Marco Chivalan with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Marco Chivalan more than expected).

Fields of papers citing papers by Marco Chivalan

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Marco Chivalan. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Marco Chivalan. The network helps show where Marco Chivalan may publish in the future.

Co-authorship network of co-authors of Marco Chivalan

This figure shows the co-authorship network connecting the top 25 collaborators of Marco Chivalan. A scholar is included among the top collaborators of Marco Chivalan based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Marco Chivalan. Marco Chivalan is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

6 of 6 papers shown
1.
Bejarano, Suyapa, et al.. (2022). Abstract P3-12-23: Characterization of triple-negative breast cancer in two Central American countries. Cancer Research. 82(4_Supplement). P3–12. 1 indexed citations
2.
Chivalan, Marco, et al.. (2022). Induction Chemotherapy with Cisplatin, Paclitaxel, and Capecitabine (PTC) in Locally Advanced (LA) Squamous Cell Carcinoma of Head and Neck (SCCHN). International Journal of Radiation Oncology*Biology*Physics. 112(5). e26–e26. 1 indexed citations
3.
Rugo, Hope S., Francisco Barrios, Marco Chivalan, et al.. (2021). Confirmed tumor response by molecular subtype in patients with metastatic breast cancer: Sub-analysis from a phase 3 clinical study comparing oral paclitaxel and encequidar to IV paclitaxel.. Journal of Clinical Oncology. 39(15_suppl). 1073–1073. 1 indexed citations
4.
Rugo, Hope S., Francisco Barrios, Marco Chivalan, et al.. (2021). Abstract PS13-06: Lower rates of neuropathy with oral paclitaxel and encequidar (oPac+E) compared to IV paclitaxel (IVPac) in treatment of metastatic breast cancer (mBC): Study KX-ORAX-001. Cancer Research. 81(4_Supplement). PS13–6. 1 indexed citations
5.
6.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Toby Talbot Breakdown of academic impact, for papers by Dorothea Hanf Breakdown of academic impact, for papers by John E. Doster Breakdown of academic impact, for papers by Graziella Bosco Breakdown of academic impact, for papers by Laura Mattheis Breakdown of academic impact, for papers by Dor Simkin Breakdown of academic impact, for papers by Chi-Wan Chow Breakdown of academic impact, for papers by Filipa Cardoso Breakdown of academic impact, for papers by Rebecca Velickovic Breakdown of academic impact, for papers by Esma’il Akade
Rankless by CCL
2026